DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Five diagnosed prevalent cases will grow to over 714,000. Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

Elizabeth Emory was 25 weeks pregnant when she learned she had stage four Burkitt non-Hodgkin lymphoma. “It was shocking, of ...

Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their ...

New data suggest that, in recent years, US cancer incidence has generally remained stable, and the rate of cancer deaths has generally decreased.

Dr. Andrew M. Evens breaks down what it means to be an adolescent or young adult with lymphoma and how treatment differs from ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.